The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)

Leukemia

Volumn 18, Issue 12, 2004, Pages 2008-2014

  Hasle, H ^a   Baumann, I ^b   Bergstrasser E ^c   Fenu, S ^d   Fischer, A ^e   Kardos, G ^f   Kerndrup, G ^g   Locatelli, F ^h   Rogge, T ^e   Schultz, K R ⁱ   Stary J ^j   Trebo, M ^k   van den Heuvel Eibrink, M M ^l   Harbott, J ^m   Nollke P ^e   Niemeyer, C M ^e  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c Department of Pediatrics ^*  (Switzerland)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF FREIBURG   (Germany)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^k ST ANNA CHILDREN S HOSPITAL   (Austria)

^l SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^m JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

Children; IPSS; JMML; MDS; Prognosis

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BLAST CELL; BONE MARROW; CHILD; CHILDHOOD DISEASE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 20244362034     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403489     Document Type: Article

References (22)

1. Passmore SJ, Hann IM, Stiller CA, Ramani P, Swansbury GJ, Gibbons B et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995; 85: 1742-1750.
2. Hasle H, Kemdrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995; 9: 1569-1572.
3. Bader-Meunier B, Mielot F, Tchernia G, Buisine J, Delsol G, Duchayne E et al. Myelodysplastic syndrome in childhood: report of 49 patients from a French multicenter study. Br J Haematol 1996; 92: 344-350.
4. Luna-Fineman S, Shannon KM, Atwater SK, Davis J, Masterson M, Ortega J et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999; 93: 459-466.
5. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106: 1027-1032.
6. Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001; 15: 1713-1720.
7. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric MDS and JMML in the UK: a population based study of incidence and survival. Br J Haematol 2003; 121: 758-767.
8. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87: 51-58.
9. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997-2003.
10. Castro-Malaspina H, Schaison G, Passe S, Pasquier A, Berger R, Bayle-Weisgerber C et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors. Cancer 1984; 54: 675-686.
11. Owen G, Lewis IJ, Morgan M, Robinson A, Stevens RF. Prognostic factors in juvenile chronic granulocytic leukaemia. Br J Cancer Suppl 1992; 18: S68-S71.
12. Niemeyer CM, Aricò M, Basso G, Cantù-Rajnoldi A, Creutzig U, Haas OA, et al., Members of the European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997; 89: 3534-3543.
13. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
14. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
15. Hasle H, Aricò M, Basso G, Biondi A, Cantù-Rajnoldi A, Creutzig U et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia 1999; 13: 376-385.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
18. Hosmer DW, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: Wiley, 1999.
19. Chang KL, O'Donnell MR, Slovak ML, Dagis AC, Arber DA, Niland JC et al. Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. Leukemia 2002; 16 623-631.
20. Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002; 20: 434-440.
21. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910-1917.
22. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16: 645-649.